Rising Incidence of Chronic Diseases Drives the Market Growth

High incidence of chronic diseases such as respiratory diseases, diabetes, cardiovascular disease and others is expected to increase the demand for the active pharmaceutical ingredients (API). According to the report of American Diabetes Association in 2018, 34.2 million or 10.5%Americans of American population had diabetes. Furthermore, diabetes is considered one of the seventh major reason of death in the U.S. as 83,564 deaths were caused because of diabetes by 2017. Thus, this signifies that the high prevalence of chronic disorders, the demand for the innovation of active pharmaceutical ingredients (API) is growing leading to market growth over the forecast period.

Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/global-active-pharmaceutical-ingredient-api-market

Data Bridge Market Research analyses that the Active Pharmaceutical Ingredient (API) Market expected to reach USD 369.56 million by 2030 from USD 223.3 million in 2021, growing with a CAGR of 6.50% in the forecast period of 2023 to 2030. Increasing investment in research regarding the expansion of active pharmaceutical ingredient (API) will likely to increase the growth of the global active pharmaceutical ingredient (API) market.

Growing utilization of advanced technology in active pharmaceutical ingredients (API) manufacturing is expected to drive the market's growth rate

The global active pharmaceutical ingredients (API) market is anticipated to grow significantly by using advanced technologies such as IoT, which increase the therapeutic activity of the finished drug products and improve the convenience of the drug products. These innovative technologies are surging the market growth. Different technologies are used to optimize active pharmaceutical ingredients (API) and finished drug products. For instance, the development of the APIs has reached digital transformation, leading to the usage of internet of things (IoT) technology and moving towards automation. The internet of things (IoT) facilities can help to facilitate the production flow in manufacturing premises because it works as an automatic monitor device which can manage the warehouses and inventories and analyze the development cycles.

Report Scope and Market Segmentation

Segment Analysis:

The active pharmaceutical ingredient (API) market is segmented on the basis of molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application.

• On the basis of molecule, global active pharmaceutical ingredients (API) market is segmented into small molecule and large molecule. Small molecule segment is expected to dominate the market with 63.78% market share owing to the growing number of regulatory approval and increasing research and development on new small molecules because of their high penetration power.
• On the basis of type, global active pharmaceutical ingredients (API) market is segmented into innovative active pharmaceutical ingredients and generic active pharmaceutical ingredients. In 2021, innovative active pharmaceutical ingredients segment is expected to dominate the market with 52.17% market share due to the high cost of innovative APIs as compare to generic APIs and increasing FDA approval for novel molecular entities.
• On the basis of type of manufacturer, global active pharmaceutical ingredients (API) market is segmented into captive API manufacturer and merchant API manufacturer. Captive API manufacturer segment is expected to dominate the market with 61.29% market share because of high investment by key players to produce high end manufacturing facilities.
• On the basis of synthesis, global active pharmaceutical ingredients (API) market is segmented into synthetic active pharmaceutical ingredients and biotech active pharmaceutical ingredients.

The synthetic active pharmaceutical ingredients segment of synthesis segment is anticipated to dominate the active pharmaceutical ingredient (API) market

Synthetic active pharmaceutical ingredients segment is expected to dominate the market with 57.47% market share because of less stringent regulatory guidelines and easy protocol for the synthesis of molecules in the upcoming year.

• On the basis of chemical synthesis, global active pharmaceutical ingredients (API) market is segmented into acetaminophen, artemisinin, saxagliptin, sodium chloride, ibuprofen, losartan potassium, enoxaparin sodium, rufinamide, naproxen, tamoxifen, and others. Saxagliptin segment is expected to dominate the market with 11.76% market share due to high price of the API and increasing cases of diabetes globally. Furthermore, saxagliptin is the new category of anti-diabetic with high efficacy.
• On the basis of type of drug, global active pharmaceutical ingredients (API) market is segmented into prescription drugs and over-the-counter drugs. Prescription drugs segment is expected to dominate the market with 53.26% market share due to the high cost of the other drugs which will increases the manufacturing cost of the APIs.
• On the basis of usage, the global active pharmaceutical ingredients (API) market is segmented into clinical and research. Clinical segment is expected to dominate the market with 66.32% market share due to increasing number of diseases which need continuous supply of APIs. Furthermore, increasing clinical trials also attributed to dominate the growth of the market.
• On the basis of potency, global active pharmaceutical ingredients (API) market is segmented into low-to-moderate potency active pharmaceutical ingredients and potent-to-highly potent active pharmaceutical ingredient.

The low-to-moderate potency active pharmaceutical ingredients segment of potency segment is anticipated to dominate the active pharmaceutical ingredient (API) market

Low-to-moderate potency active pharmaceutical ingredients segment is expected to dominate the market with 56.52% market share due to their less hazard nature and less toxicity.

• On the basis of therapeutic application, global active pharmaceutical ingredients (API) market is segmented into cardiology, CNS & neurology, oncology, orthopedic, endocrinology, pulmonology, gastroenterology, nephrology, ophthalmology, and other therapeutic application. Hospital pharmacy segment is expected to dominate the market with 19.05% market share due to increasing number of cardiac disease such as embolism, heart attack and others.

Major Players

Data Bridge Market Research recognizes the following companies as the major active pharmaceutical ingredient (API) market players in active pharmaceutical ingredient (API) market Novartis AG (Switzerland), Sanofi (France). Pfizer Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Abbott (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Bausch Health Companies Inc. (Canada), UCB S.A. (Belgium), Sunovion Pharmaceuticals Inc. (U.S.), Jazz Pharmaceuticals, Inc. (U.K.).

Market Development

• In 2020, Bright Path Laboratories and Quartic.ai signed a contract to produce active pharmaceutical ingredients (APIs) using artificial intelligence technology. Artificial intelligence (AI) is one of the innovative and advanced platforms for the drug discovery. The contract was signed which comprises Quartic.ai AI technology can surge the speed of the design, approval and validation of AI-based active pharmaceutical ingredients (API). Bright Path Laboratories will use their flow Spinning Tube-in-Tube technology which can form high amount of APIs and chemicals which will deliver high pure grade product. The combination of these technologies will increase their product portfolio in terms of innovative products.
• In 2020, CordenPharma International declared the accomplishment of its highly potent API laboratory in Colorado. This new laboratory will be involved in the commercialization and manufacturing of the APIs and the goal of the company's goal was to fulfill the customers' demand. This aided the company to increase their product portfolio and increase their revenues in the upcoming period.

 Regional Analysis

Geographically, the countries covered in the active pharmaceutical ingredient (API) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in active pharmaceutical ingredient (API) market during the forecast period 2023 to 2030

North America dominates the active pharmaceutical ingredient (API) market owing to the well-established healthcare infrastructure and growing healthcare expenditures in this region. Furthermore, the presence of major key players and higher adoption of synthetic active pharmaceutical ingredient (API) will further enhance the market growth in this region.  

Asia-Pacific is estimated to be the fastest-growing region in active pharmaceutical ingredient (API) market the forecast period 2023 to 2030

Asia-Pacific is expected to grow during the forecast period of 2023 to 2030 owing to the augmented consumption demand for the active pharmaceutical ingredients in this region. Additionally, the increasing development of healthcare infrastructure and growing government initiatives are some of the other major factors that will further boost this region's market growth. 

For more detailed information about active pharmaceutical ingredient (API) market report, click here – https://www.databridgemarketresearch.com/fr/reports/global-active-pharmaceutical-ingredient-api-market